

Rolapitant

Catalog No: tcsc6387



Available Sizes

Size: 5mg

Size: 10mg

Size: 25mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

552292-08-7

Formula:

$C_{25}H_{26}F_6N_2O_2$

Pathway:

Neuronal Signaling;GPCR/G Protein

Target:

Neurokinin Receptor;Neurokinin Receptor

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 30 mg/mL (59.94 mM)

Alternative Names:

SCH619734

Observed Molecular Weight:

500.48


Product Description

Rolapitant (SCH619734) is a potent, selective and orally active **neurokinin** NK1 receptor antagonist with a **K_i** of 0.66 nM.

IC50 & Target: K_i: 0.66 nM (neurokinin)^[1]

In Vitro: Rolapitant has a high affinity for the human NK1 receptor with a K_i of 0.66 nM and high selectivity over the human NK2 and NK3 subtypes of more than 1000-fold, as well as preferential affinity for human, guinea pig, gerbil and monkey NK1 receptors over rat, mouse and rabbit^[1].

In Vivo: Rolapitant reverses NK1 agonist-induced foot tapping in gerbils following both intravenous and oral administration up to 24 hours at a minimal effective dose (MED) of 0.1 mg/kg. Rolapitant is active at 0.1 and 1 mg/kg in both acute and delayed emesis models in ferrets, respectively, consistent with clinical data for other NK1 antagonists. Clinical efficacy of anti-emetics is highly correlated with efficacy in the ferret emesis model, suggesting rolapitant is a viable clinical candidate for this indication^[1].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!